ReviewCurrent hematologic malignancy reports2011
In search of CML stem cells' deadly weakness.
Review in Current hematologic malignancy reports, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 22 citations in OpenAlex.
- Chronic myeloid leukemia stem cells and molecular target therapies for overcoming resistance and disease persistence.International journal of hematology · 2018Review
- The Polycomb BMI1 Protein Is Co-expressed With CD26+ in Leukemic Stem Cells of Chronic Myeloid Leukemia.Frontiers in oncology · 2018Article
- MiR-15a-5p negatively regulates cell survival and metastasis by targeting CXCL10 in chronic myeloid leukemia.American journal of translational research · 2017Article
- Epigenetic Reprogramming Sensitizes CML Stem Cells to Combined EZH2 and Tyrosine Kinase Inhibition.Cancer discovery · 2016Article
- MicroRNA-130a regulates cell malignancy by targeting RECK in chronic myeloid leukemia.American journal of translational research · 2016Article
- Functional studies of miR-130a on the inhibitory pathways of apoptosis in patients with chronic myeloid leukemia.Cancer gene therapy · 2015Article
- MicroRNAs in Myeloid Hematological Malignancies.Current genomics · 2015Article
- From the Biology of PP2A to the PADs for Therapy of Hematologic Malignancies.Frontiers in oncology · 2015Review
- Article
- Genetic events other than BCR-ABL1.Current hematologic malignancy reports · 2014Review
- IL1RAP as a surface marker for leukemia stem cells is related to clinical phase of chronic myeloid leukemia patients.International journal of clinical and experimental medicine · 2014Article
- PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells.The Journal of clinical investigation · 2013Article
- Protein phosphatase 2A: a target for anticancer therapy.The Lancet. Oncology · 2013Review
- Recent advances in acute myeloid leukemia stem cell biology.Haematologica · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Chronic myeloid leukemia (CML) is a clonal myeloproliferative disorder that is characterized by the presence of a fusion oncogene, BCR-ABL, which encodes a protein with constitutive tyrosine kinase activity. This activity causes excessive production of myeloid cells and their premature release into the circulation. The discovery of tyrosine kinase inhibitors marked a major advance in CML therapy, but these drugs cannot eradicate the disease because they are unable to kill the most primitive, quiescent leukemic stem cells. This review discusses current research in CML and attractive targets that have emerged with potential for eradicating the disease. Several new targets have recently been investigated as potential modulators in myeloid leukemia pathogenesis, including the multiple gene regulators miRNAs, the apparently leukemia-specific cell surface marker IL1RAP, transcription factors such as BMI1 and FOXOs, the tumor suppressors PML and PP2A, and the tyrosine kinase JAK2.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.